CRMD at a glance
CorMedix Inc. (CRMD, SEC CIK 1410098) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), CorMedix Inc. (CRMD) reported revenue of $311.7 million (up 617.0% from FY2024) and net income of $163.1 million. Diluted EPS was $2.04.
- As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding CorMedix Inc. (CRMD) shares worth $139.8 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Blum Susan on November 19, 2026 of 5,000 shares at $4.58 per share.
- In the last 90 days, CRMD insiders reported 4 open-market purchases ($588K) and 0 open-market sales ($0) on Form 4, a net purchase of $588K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $311.7M
- +617.0% vs prior year
- Insiders · 90 days
- 4 buys · 0 sells
- Net +$588K
- 13F holders
- 30 funds
- $139.8M · +2 vs prior quarter
- Latest 8-K
- Nov 16, 2026
- Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Acquisition risk: Heron transaction may fail closing conditions or stockholder vote, pressuring share price and results
- Regulatory risk: CMS post-TDAPA adjustment reduced DefenCath net pricing in 2H 2026
- Reimbursement risk: Quarterly CMS calculations begin in 2027, increasing DefenCath revenue volatility
- Financial risk: Proposed $150 million senior secured term loan would increase interest costs and repayment obligations
- Dilution risk: Heron would receive 14,583,333 shares, representing approximately 18.3% pro forma ownership
Management Discussion & Analysis
- Revenue $54.5M, down 48% YoY from $104.3M, driven by lower DefenCath net pricing
- Gross margin 55.0% vs 89.3% YoY, with net income $14.7M loss vs $108.6M income
- DefenCath worst performer, product sales $17.2M vs $88.8M; Melinta Portfolio sales $31.4M vs $12.8M
- Cash and investments $355.2M vs $148.5M at December 31, 2025; operating cash flow $218.3M year to date
- CMS reimbursement headwind: $8.32 add-on effective January 2027, expected 2027 average at least twice $2.37 current rate
AI summary of the CRMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- Conference call discussed CorMedix’s financial results for quarter ended September 30, 2026
- Full investor-call transcript furnished as Exhibit 99.1, containing management commentary and financial-results details
Item EX-99.1: Item EX-99.1
- Q3 revenue $54.5M, down from $104.3M, reflecting DefenCath pricing pressure after post-TDAPA transition
- DefenCath sales $17.2M, with dialysis utilization largely maintained at the $2.37 add-on rate
Item 2.02: Results of Operations and Financial Condition
- CorMedix announced financial results for the quarter ended September 30, 2026
- Investor-relevant figures and management commentary are contained in Exhibit 99.1, the accompanying earnings release
Item EX-99.1: Item EX-99.1
- Q3 revenue $54.5M, down from $104.3M, reflecting DefenCath pricing pressure after post-TDAPA transition
- DefenCath revenue $17.2M, including a $5.0M favorable sales-allowance estimate change, signaling underlying pricing sensitivity
Item 7.01: Regulation FD Disclosure
- Proposed acquisition of substantially all Heron assets, adding four FDA-approved commercial brands to CorMedix’s portfolio
- Transaction expected to diversify revenue, generate synergies and be earnings accretive, subject to closing conditions
Item EX-99.2: Item EX-99.2
- Proposed asset acquisition adds four FDA-approved brands, including ZYNRELEF, APONVIE, CINVANTI and SUSTOL
- Upfront consideration: $145 million cash plus 14,583,333 CorMedix shares valued at $7.20 each
Item EX-99.1: Item EX-99.1
- Heron acquisition adds 4 commercial products and approximately $150 million in trailing 12-month net product revenue
- Upfront consideration: $145 million cash plus approximately 14.6 million CorMedix shares, valued at approximately $77.6 million at $5.32
AI summaries of CRMD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CRMD
Don't miss the next CRMD filing
- Alerts as it files. A push when CRMD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CRMD, by share count.
- Ask anything. An AI agent that reads every CRMD filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Blum Susan | Buy | Nov 19, 2026 | 5,000 | $4.58 |
| Lefkowitz Steven W | Buy | Nov 18, 2026 | 11,500 | $4.53 |
| Kaplan Myron | Buy | Nov 16, 2026 | 25,000 | $4.88 |
| Todisco Joseph | Buy | Nov 13, 2026 | 80,000 | $4.89 |
| Dillione Janet | M | Sep 18, 2026 | 48,909 | - |
| Dillione Janet | M | Sep 18, 2026 | 48,909 | - |
| Zelnick Kaufman Beth | F | Aug 29, 2026 | 8,424 | $8.30 |
| Blum Susan | F | Aug 29, 2026 | 8,424 | $8.30 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $43.5M | $311.7M |
| Gross Profit | - | $40.3M | $275.7M |
| Operating Income | - | -$22.4M | $150.1M |
| Net Income | - | -$17.9M | $163.1M |
| Gross Margin | - | 92.7% | 88.5% |
| Op. Margin | - | -51.4% | 48.2% |
| Net Margin | - | -41.2% | 52.3% |
| Balance Sheet | |||
| Total Assets | $82.1M | $118.8M | $826.1M |
| Equity | - | $84.7M | $405.3M |
| ROE | - | -21.2% | 40.2% |
| Per Share | |||
| EPS | - | $-0.30 | $2.04 |
| Cash Flow | |||
| Operating CF | - | -$50.6M | $175.0M |
| CapEx | $327K | $116K | $2.3M |
Source: XBRL data in CorMedix Inc. (CRMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate CRMD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 30 | $139.8M |
| Q2 2026 | 28 | $128.8M |
| Q1 2026 | 26 | $107.2M |
| Q4 2025 | 25 | $201.8M |
| Q3 2025 | 25 | $213.2M |
| Q2 2025 | 26 | $207.5M |
| Q1 2025 | 22 | $53.6M |
| Q4 2024 | 19 | $57.6M |
- Goldman Sachs Group+783.0K (+168%)
- State Street Corp+320.6K (+14%)
- Morgan Stanley+217.8K (+51%)
- JPMorgan Chase & Co+195.3K (+290%)
- D.E. Shaw & Co+158.7K (+92%)
- Raymond James Financial−87.1K (-20%)
- Vanguard Capital Management LLC−83.5K (-3%)
- AQR Capital Management−64.9K (-43%)
- Wells Fargo & Co−45.6K (-66%)
- Northern Trust−38.1K (-5%)
- FMR LLC (Fidelity)−6.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 201 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CRMD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 20, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 8-K | Nov 16, 2026 | - | Analysis | - |
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 8-K | Nov 10, 2026 | - | Analysis | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 8-K | Nov 2, 2026 | - | Analysis | - |
| 8-K | Oct 19, 2026 | - | Analysis | - |
| 4 | Sep 18, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 4 | Sep 1, 2026 | - | - | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 8-K | Aug 7, 2026 | - | Analysis | - |
| 8-K | Jul 2, 2026 | - | Analysis | - |
| 8-K | Jul 1, 2026 | - | Analysis | - |
| 8-K | Jun 24, 2026 | - | Analysis | - |
| 8-K | Jun 8, 2026 | - | Analysis | |
| 10-Q | May 14, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 14, 2026 | - | - | |
| 8-K | Apr 27, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
CRMD SEC filings: frequently asked questions
Are CRMD insiders buying or selling?
In the last 90 days, CorMedix Inc. (CRMD) officers, directors and 10% owners reported 4 open-market purchases worth $588,195 by 4 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CRMD stock?
As of September 30, 2026, the largest CorMedix Inc. (CRMD) holders among the 13F filers tracked by SignalX were BlackRock ($49.7 million), Vanguard Capital Management LLC ($23.5 million), State Street Corp ($20.3 million), Goldman Sachs Group ($9.6 million), Vanguard Portfolio Management LLC ($5.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CRMD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), CorMedix Inc. (CRMD) reported revenue of $311.7 million (up 617.0% from FY2024) and net income of $163.1 million. Diluted EPS was $2.04. The figures come from the XBRL data in the 10-K.
What did CRMD report in its latest 8-K?
CorMedix Inc. (CRMD) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure). Conference call discussed CorMedix’s financial results for quarter ended September 30, 2026.
What are the latest CRMD SEC filings?
CorMedix Inc. (CRMD) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on November 20, 2026.
What is CRMD's SEC CIK number?
CorMedix Inc. (CRMD)'s SEC Central Index Key (CIK) is 1410098. EDGAR lists every CRMD filing under that number.
Ask anything about CRMD
The research agent reads CRMD's filings, financials, insider trades and 13F holders, then answers with sources.